CY1117519T1 - METHOD OF TREATMENT OF DIFFERENTIAL DISORDERS AND OTHER PATHOLOGICAL CONDITIONS CAUSED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R ACTIVATOR - Google Patents

METHOD OF TREATMENT OF DIFFERENTIAL DISORDERS AND OTHER PATHOLOGICAL CONDITIONS CAUSED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R ACTIVATOR

Info

Publication number
CY1117519T1
CY1117519T1 CY20161100423T CY161100423T CY1117519T1 CY 1117519 T1 CY1117519 T1 CY 1117519T1 CY 20161100423 T CY20161100423 T CY 20161100423T CY 161100423 T CY161100423 T CY 161100423T CY 1117519 T1 CY1117519 T1 CY 1117519T1
Authority
CY
Cyprus
Prior art keywords
treatment
ddr1
ddr2
bcr
pdgf
Prior art date
Application number
CY20161100423T
Other languages
Greek (el)
Inventor
Neil Gallagher
Ophelia Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10781781.9A external-priority patent/EP2501384B2/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1117519T1 publication Critical patent/CY1117519T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μια αγωγή για τη χορήγηση μιας πυριμιδυλ-αμινοβενζαμίδης του χημικού τύπου (I) όπου οι ρίζες έχουν τις σημασίες που δόθηκαν πιο πάνω στο παρόν κείμενο, ή με ένα φαρμακευτικά αποδεκτό άλας αυτού, για τη θεραπεία πολλαπλασιαστικών διαταραχών, και ιδίως στερεών και υγρών όγκων, και άλλων παθολογικών καταστάσεων που προκαλούνται από την ογκοπρωτεΐνη Bcr-Abl, τον υποδοχέα κινάσης τυροσίνης της κυτταρικής διαμεμβράνης c-Kit, την δραστηριότητα κινάσης DDR1 (υποδοχέας δισκοϊδίνης 1), DDR2 (υποδοχέας δισκοϊδίνης 2) ή PDGF-R (υποδοχέας αυξητικού παράγοντα που προέρχεται από αιμοπετάλια), όπου η πυριμιδυλαμινοβενζαμίδη του χημικού τύπου (I) και, επιλεκτικά, φαρμακευτικά αποδεκτοί φορείς, είναι διασπειρόμενη σε ένα σκεύασμα από φρούτο.The present invention relates to a treatment for the administration of a pyrimidyl aminobenzamide of formula (I) wherein the radicals have the meanings given hereinabove, or a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, in particular solid and liquid tumors, and other pathologies caused by the Bcr-Abl oncoprotein, the cell membrane tyrosine kinase receptor c-Kit, DDR1 (discoidin 1 receptor) kinase activity, DDR2 (PDGF-2 receptor) receptacle platelet-derived growth factor), wherein the pyrimidylaminobenzamide of formula (I) and, selectively, pharmaceutically acceptable carriers, is dispersible in a fruit preparation.

CY20161100423T 2009-11-17 2016-05-17 METHOD OF TREATMENT OF DIFFERENTIAL DISORDERS AND OTHER PATHOLOGICAL CONDITIONS CAUSED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R ACTIVATOR CY1117519T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26181209A 2009-11-17 2009-11-17
EP10781781.9A EP2501384B2 (en) 2009-11-17 2010-11-17 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity

Publications (1)

Publication Number Publication Date
CY1117519T1 true CY1117519T1 (en) 2017-04-26

Family

ID=58606688

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100423T CY1117519T1 (en) 2009-11-17 2016-05-17 METHOD OF TREATMENT OF DIFFERENTIAL DISORDERS AND OTHER PATHOLOGICAL CONDITIONS CAUSED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R ACTIVATOR

Country Status (1)

Country Link
CY (1) CY1117519T1 (en)

Similar Documents

Publication Publication Date Title
JO3634B1 (en) Method of treating proliferative disorders and other ‎pathological conditions mediated by bcr-abl, c-kit, ddr1, ‎ddr2 or pdgf-r kinase activity
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
EA201591906A1 (en) UREA DERIVATIVES USEFUL AS KINASE INHIBITORS
CY1117097T1 (en) PYRIDONES AND AZA-PYRIDONES HYDROSYLOR UNIONS AS SUSPENSIONS OF BTK ACTION
TN2012000150A1 (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
EA200901611A1 (en) DERIVATIVES 2-OXO-3-BENZYL-BENZOXAZOL-2-SHE AND RELATED COMPOUNDS AS METERS KINASE INHIBITORS FOR TREATMENT
MX2011012353A (en) N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS.
EA201790228A1 (en) COMPOSITIONS AND METHODS OF OBTAINING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITING ACTIVITY
EA201000092A1 (en) TRIPLE-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TN2015000355A1 (en) PYRROLO [2, 3-D] PYRIMIDINE DERIVATIVES AS JANUS-TYPE KINASE INHIBITORS (JAK)
EA201490891A1 (en) PYRIDOPYRAZINS, possessing anti-cancer activity through inhibition of FGFR kinase
EA201001242A1 (en) PYRROLO [2,3-d] Pyridine and THEIR APPLICATION AS THYROZINKINASE INHIBITORS
UA101611C2 (en) Compounds of imidazo[1,2-a]pyridine as receptor tyrosine kinase inhibitors
CY1113642T1 (en) BRIDGED BICYCLE HETEROYLIC Substituted Triazoles, Useable as AXL Suspensions
MA34042B1 (en) PYRROLO [2, 3. B] PYRIDINES THAT INHIBIT RAF PROTEIN KINASE
MX353308B (en) Phosphorous derivatives as kinase inhibitors.
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2012014017A (en) Heteroaryl imidazolone derivatives as jak inhibitors.
EA201100966A1 (en) PYRIDAZINON DERIVATIVES
MX2009009117A (en) Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors.
EA200901603A1 (en) ARYL-ESSENTIAL DERIVATIVES OF PYRIDAZINONE
MX2012013274A (en) Novel pyrimidine derivatives.
EA201201081A1 (en) HIGHLIGHTS [1,8] NOTE
EA201400595A1 (en) MORFOLINYLBENZOTRIAZINES FOR USE IN CANCER TREATMENT
ATE481972T1 (en) QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS